Peptable

Comparison

BPC-157 vs Exenatide

Function

While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768.

Mechanism

While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, Exenatide is a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67.

Receptor

BPC-157

VEGFR2 (vascular endothelial growth factor receptor 2) on endothelial cells, with downstream eNOS and nitric-oxide–mediated signaling11

Exenatide

GLP-1 receptor (GLP1R) 6780

Organism or Origin

BPC-157

Synthetic peptide derived from a naturally occurring human gastric 'Body Protection Compound' isolated from human gastric juice111

Exenatide

Originally from Heloderma suspectum (Gila monster) venom; now produced synthetically67

Gene

BPC-157

Not assigned in the current dataset.

Exenatide

Not assigned in the current dataset.

Summary

BPC-157 and Exenatide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: BPC-157 is more often discussed in the realm of Gastroenterology, Musculoskeletal health, and Dermatology and aesthetics, whereas Exenatide is more often associated with the realm of Metabolic and endocrine. Their biological logic is quite different: BPC-157 is a signaling modulator, whereas Exenatide is a receptor agonist. BPC-157 has a more synthetic analog origin, while Exenatide is closer to venom-derived background and their development context also differs, with BPC-157 in Preclinical development while Exenatide is approved. Exenatide incorporates amidation features that are not part of BPC-157, while their sequence patterns also diverge, with BPC-157 showing proline-rich features and Exenatide showing alpha-helical domain features.

Sources

11BPC-157 - Wikipedia, https://en.wikipedia.org/wiki/BPC-157
67Exendin 4 – Potent GLP-1R agonist - SB PEPTIDE, https://www.sb-peptide.com/project/exendin-4-potent-glp-1r-agonist/
68Glucagon-like peptide-1 analogues: An overview - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3712370/
80GLP-1 Localisation and Proglucagon Gene Expression in ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6200298/